Novartis - Heart Failure - Primary Endpoints, page-66

Ah MSB have failed to meet the PE on its last 3 trials.

Given it leveraged itself heavily for aGVHD approval, it now finds itself with a capital squeeze to leverage from the possibilities that come from secondary endpoints and the favourite post hoc analysis.

It strategised heavily that all trials would succeed.

And that the FDA would agree with the MSB view of proof of potency for RemL.

Now with limited cash to fund debt, let alone research recent trial findings, it is in the hands of capital markets and big pharma.

As all on here say, capital markets and big pharma play less than nice.

Aloha!